Default company panoramic image
Otonexus logo 20large

OtoNexus Medical Technologies, Inc.

OtoNexus is commercializing the world’s first medical device for the instant and accurate diagnosis of Otitis Media, which affects millions and costs billions.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Seattle, WA, USA
  • Currency USD
  • Founded December 2010
  • Employees 5
  • Incorporation Type C-corp
  • Website otonexus.com

Company Summary

OtoNexus is developing a ground-breaking, patented ultrasound device to rapidly & accurately diagnose Otitis Media (OM). 17.6 Million patient visits each year are coded to OM at a cost of more than $5 Billion/year, yet clinical studies show a 50% error rate in diagnosis. OM is the #1 reason for antibiotics and the #1 cause for surgery in children. Definitive, objective diagnostic data will lead to earlier & better treatment & reduced costs.

Team

  • Default avatar
    Caitlin E. Cameron
    Chairman & CEO

    Ms. Cameron is a highly accomplished senior executive & Angel investor with 30 years’ cross-industry expertise in the Life Sciences, Biotech, Technology, and IT industries. She is a specialist in building successful businesses and has held Chair & CEO positions at many companies, creating value and maximizing potential in a very short period of time. Her leadership has led to her company being selected for the 100 Best Places to Work in WA.

  • Default avatar
    George A. Gates, MD
    Founder, Chief Medical Officer, Member of the Board

    Dr. Gates is an internationally recognized clinician and medical researcher, with more than 40 years’ experience in the diagnosis and treatment of Otitis Media. Dr. Gates is an otolaryngologist and neurotologist, and is an Emeritus Professor at the University of Washington (UW) and former director of the Bloedel Hearing Research Center. He has authored 220 peer-reviewed published articles, and he is the inventor of our technology.

  • Default avatar
    Mark A. Moehring, PhD
    VP of R&D, Chief Technology Officer, Member of the Board

    Dr. Moehring is an internationally recognized Medical Doppler Ultrasound and Signal Processing Engineer and expert. Dr. Moehring is co-inventor on our patent along with Dr. Gates, and was instrumental in developing the design, testing the proof-of-concept, and successfully completing the patent process for our technology. He utilizes his extensive expertise in Doppler Ultrasound in leading the engineering and R&D aspects of the company.

  • Default avatar
    Rhonda F. Rhyne
    Member of the Board

    Ms. Rhyne has over 25 years of experience in health care with both public and private companies, as well as a health care provider. She is President and CEO of Prevencio Medical. She was President of Cardio-Dynamics from 1997 until 2009, when the publicly-traded company was sold to SonoSite. Previously, Ms. Rhyne was CEO and Director at Culture Technology, and held sales and sales management positions at GE Healthcare and Cardiac Science.

Advisors

  • Default avatar
    Wilson Sonsini Goodrich & Rosati
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    T3DC
    Unconfirmed
    Default avatar
    Keiretsu Forum
    Unconfirmed
    Default avatar
    Many Angel investors
    Unconfirmed